SCHEMBL2593542

SCHEMBL2593542

CCOC(=O)C(C#N)=C(C=CN(C)C)OCC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.51
ALDH1A1 P00352 5/20 0.42
TSHR P16473 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 4/20 0.36
KDM4E B2RXH2 4/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.34
USP2 O75604 2/20 0.34
RAB9A P51151 2/20 0.34
LMNA P02545 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
POLB P06746 1/20 0.33
PTP4A1 Q93096 1/20 0.33
MIF P14174 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2593541 1.00 CYP2C9 (0.51) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL9869703 1.00 CYP2C9 (0.51) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL15313611 1.00 CYP2C9 (0.51) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL17091307 0.91 CYP2C9 (0.49) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL25533356 0.91 CYP2C9 (0.45) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL17091305 0.91 CYP2C9 (0.49) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL30174225 0.91 CYP2C9 (0.45) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL3660855 0.88 CYP2C9 (0.44) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL3660857 0.88 CYP2C9 (0.44) CYP2C9ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL1261134 0.86 CYP2C9 (0.53) CYP2C9ALDH1A1TSHRL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120737256-A High-light-transmittance contact lens silicon hydrogel material and preparation method thereof 爱睿思(厦门)科技有限公司 2025-10-03 CN disclosed
CN-111196814-B Aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof 北京赛特明强医药科技有限公司 2022-12-06 CN disclosed
US-20220002308-A1 AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2022-01-06 US disclosed
EP-3865487-A1 AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-08-18 EP disclosed
CN-111196814-A Aromatic ring connecting dioxane quinazoline or quinoline compound, composition and application thereof 北京赛特明强医药科技有限公司 2020-05-26 CN disclosed
US-9387202-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2016-07-12 US disclosed
US-20150148380-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2015-05-28 US disclosed
US-9012635-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-04-21 US disclosed
US-8921565-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-12-30 US disclosed
US-20140343103-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-11-20 US disclosed
EP-2782577-A2 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, LLC. (US) 2014-10-01 EP disclosed
WO-2014145004-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 WO disclosed
US-20130317066-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, INC. (US) 2013-11-28 US disclosed
US-8569319-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities Deciphera Pharmaceuticals, LLS (US) 2013-10-29 US disclosed
WO-2013078295-A2 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-05-30 WO disclosed
EP-2563773-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES Deciphera Pharmaceuticals, LLC (US) 2013-03-06 EP disclosed
US-20120172382-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC. (US) 2012-07-05 US disclosed
WO-2011139891-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES DECIPHERA PHARMACEUTICALS, LLC (US) 2011-11-10 WO disclosed
US-4987232-A ONE POT, GOOD YIELD SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ, B.V. (NL) 1991-01-22 US disclosed
EP-0372654-A2 Preparation of 2-chloropyridine 3-carboxylic acid esters SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1990-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148380-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES MKI67, TYMP, CCNA1 CYP2C9 3035/4885ALDH1A1 250/4885TSHR 2946/4885
US-20130317066-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES MKI67, TYMP, CCNA1 CYP2C9 3035/4885ALDH1A1 250/4885TSHR 2946/4885
US-20120172382-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES MKI67, TYMP, CCNA1 CYP2C9 3035/4885ALDH1A1 250/4885TSHR 2946/4885
US-20220002308-A1 AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF MERTK, AXL, TYRO3 CYP2C9 876/4885ALDH1A1 2479/4885TSHR 232/4885
US-20140343103-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES MKI67, TYMP, CCNA1 CYP2C9 3035/4885ALDH1A1 250/4885TSHR 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.